These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 11115593)

  • 1. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
    Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
    Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
    Yonemoto M; Satoh T; Arakawa H; Suzuki-Takahashi I; Monden Y; Kodera T; Tanaka K; Aoyama T; Iwasawa Y; Kamei T; Nishimura S; Tomimoto K
    Mol Pharmacol; 1998 Jul; 54(1):1-7. PubMed ID: 9658183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK; Windle JJ; Von Hoff DD
    J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
    J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein farnesyltransferase inhibitors.
    Ayral-Kaloustian S; Salaski EJ
    Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costunolide, a sesquiterpene from the stem bark of Magnolia sieboldii, inhibits the RAS-farnesyl-proteintransferase.
    Park SH; Choi SU; Lee CO; Yoo SE; Yoon SK; Kim YK; Ryu SY
    Planta Med; 2001 Jun; 67(4):358-9. PubMed ID: 11458455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
    J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue.
    Tahir SK; Gu WZ; Zhang HC; Leal J; Lee JY; Kovar P; Saeed B; Cherian SP; Devine E; Cohen J; Warner R; Wang YC; Stout D; Arendsen DL; Rosenberg S; Ng SC
    Eur J Cancer; 2000 Jun; 36(9):1161-70. PubMed ID: 10854950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
    Du W; Lebowitz PF; Prendergast GC
    Cancer Res; 1999 May; 59(9):2059-63. PubMed ID: 10232587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
    Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
    Int J Cancer; 1999 Mar; 80(6):911-8. PubMed ID: 10074926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
    Nakamura K; Yamaguchi A; Namiki M; Ishihara H; Nagasu T; Kowalczyk JJ; Garcia AM; Lewis MD; Yoshimatsu K
    Oncol Res; 2001; 12(11-12):477-84. PubMed ID: 11939411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K; Nagasu T
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
    Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
    Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arglabin: From isolation to antitumor evaluation.
    Lone SH; Bhat KA; Khuroo MA
    Chem Biol Interact; 2015 Oct; 240():180-98. PubMed ID: 26327249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.